Press Room

Two-year $300 Million Extension of the Special Diabetes Program Allows for the Continuation of Promising Ongoing Clinical Trials

The U.S. Senate overwhelmingly approved legislation last night for a two-year extension of the Special Diabetes Program (SDP)—an initiative that accounts for roughly one-third of all Federally-funded type 1 diabetes (T1D) research in the United States. The decision comes on the heels of the strong ...


JDRF-Supported Researchers Make Gains in Designing Islet Cell Encapsulation Materials for Use in Type 1 Diabetes Therapies

New study shows size and shape of encapsulation materials have an effect on islet cell survival


BD and Medtronic Collaborate to Introduce a New Infusion Set with BD FlowSmart Technology Designed to Improve Insulin Pump Therapy

BD Medical, a segment of leading global medical technology company BD (Becton, Dickinson and Company) (NYSE: BDX), and Medtronic (NYSE: MDT) today announced a collaboration to introduce a new insulin pump infusion set with BD FlowSmart™ technology​


BD Receives FDA Clearance for a Novel Infusion Set with BD FlowSmart Technology to Enhance the Use of Insulin Pumps

BD Medical, a segment of leading global medical technology company BD (Becton, Dickinson and Company) (NYSE: BDX), announced today it has received 510(k) clearance from the U.S. Food and Drug Administration for a new insulin infusion set with BD FlowSmartTM  technology. 


14-Year-Old from Vancouver to Represent Canada at JDRF 2015 Children's Congress

Jack, 14 of Vancouver, has big plans for this summer. He has been selected by JDRF to join 160 other children from around the world in Washington, D.C., to remind U.S. Members of Congress of the vital need to continue supporting research that aims to reduce the burden they all share of living ...


REGiMMUNE Announces Collaboration with JDRF and Pfizer Inc. for Type 1 Diabetes Prevention and Treatment Promoting Regulatory T-Cells

REGiMMUNE Corporation (RGI) and JDRF today announced a partnership, along with financial assistance and scientific expertise from Pfizer Inc., for a research collaboration to develop an antigen-specific immunotherapy utilizing RGI’s proprietary αGalCer/liposome platform ...


JDRF in the Globe and Mail, April 1, 2015: Improving the chances for healthy pregnancies.

JDRF showcases the CONCEPPT trial, including quotes from Dr. Lois Donovan, Medical Director of diabetes in pregnancy in Calgary - Alberta Health Services and Dr. Helen Murphy in Cambridge, U.K., who are co-principal investigators overseeing Canadian and international sites. The story also provides ...


ViaCyte Receives Clearance from Health Canada for Diabetes Clinical Trial

ViaCyte, Inc., a privately-held regenerative medicine company with the first stem cell-derived islet replacement therapy for the treatment of diabetes in clinical trials, has received a No Objection Letter from Health Canada providing clearance to proceed with sites in Canada for the Company's ...


JDRF Announces New Partnership with the European Foundation for the Study of Diabetes and Eli Lilly and Company to Fund Novel Diabetes Research

JDRF, the leading research and advocacy organization funding type 1 diabetes (T1D) research announced today a new research partnership with the European Foundation for the Study of Diabetes (EFSD) and Eli Lilly and Company to establish a new research funding program to accelerate type 1 diabetes discovery ...


Stem cells show promise for reversing Type 2 diabetes

Scientists at the University of British Columbia and BetaLogics, part of Janssen Research & Development, LLC have shown for the first time that Type 2 diabetes can be effectively treated with a combination of specially-cultured stem cells and conventional diabetes drugs.


Lets turn type one into type none